DFO
NKTR icon

Duquesne Family Office’s Nektar Therapeutics NKTR Stock Holding History

Duquesne Family Office’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-66,667
Closed -$18M – 57
2021
Q3 		$18M Hold
66,667
– – 0.58% 31
2021
Q2 		$17.2M Hold
66,667
– – 0.43% 39
2021
Q1 		$20M Buy
+66,667
New +$20.7M 0.44% 48
2020
Q1 		– Sell
-20,705
Closed -$6.7M – 59
2019
Q4 		$6.7M Buy
+20,705
New +$6M 0.2% 49
2018
Q2 		– Sell
-79,487
Closed -$127M – 37
2018
Q1 		$127M Sell
79,487
-42,780
-35% -$55.1M 7% 6
2017
Q4 		$110M Buy
122,267
+44,527
+57% +$26.3M 5.52% 6
2017
Q3 		$28M Hold
77,740
– – 1.27% 19
2017
Q2 		$22.8M Buy
77,740
+33,367
+75% +$9.64M 1.22% 25
2017
Q1 		$15.6M Buy
+44,373
New +$9.97M 1.02% 30
2016
Q4 		– Sell
-38,140
Closed -$9.83M – 53
2016
Q3 		$9.83M Buy
+38,140
New +$9.82M 0.87% 38
2015
Q2 		– Sell
-43,667
Closed -$7.21M – 39
2015
Q1 		$7.21M Hold
43,667
– – 0.92% 23
2014
Q4 		$10.2M Buy
+43,667
New +$9.33M 1% 31

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Duquesne Family Office's NKTR Position: Q4 2021 in Review

Duquesne Family Office sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 66,667 shares — an estimated $18M sold.

Duquesne Family Office first reported a position in NKTR in Q4 2014 and held it in 12 quarters. The position peaked at $127M in Q1 2018. 241 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Duquesne Family Office reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Duquesne Family Office sold 66,667 Nektar Therapeutics shares in Q4 2021, an estimated $18M.
  • Duquesne Family Office first reported a position in Nektar Therapeutics in Q4 2014 and held it in 12 quarters.
  • Duquesne Family Office's Nektar Therapeutics position peaked at $127M in Q1 2018.
  • 241 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Duquesne Family Office's 13F filing for Q4 2021, filed 14 Feb 2022.